Navigation Links
Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
Date:9/16/2008

Covers Development of Gene Expression Signatures Derived by COXEN Algorithm

as Molecular Test of Responsiveness to Current Treatments

OMAHA, Neb., and CHARLOTTESVILLE, Va., Sept. 16 /PRNewswire-FirstCall/ -- Transgenomic (OTC Bulletin Board: TBIO) today announced a partnership with Key Genomics to develop a molecular diagnostic test which will guide clinicians in their choice of currently available treatments for ovarian cancer. The new test will be powered by Key Genomics' predictive algorithm, COXEN ("CO-eXpression ExtrapolatioN").

Ovarian cancers are often diagnosed at the advanced stage of disease, after the tumor has spread beyond the ovary. Initial investigation of COXEN-derived genomic signatures in clinical trials has demonstrated that the test can distinguish responders from patients who do not benefit from a therapy. "Getting the patient the best therapeutic option as quickly as possible is a key factor in survival," commented Craig Tuttle, CEO of Transgenomic. "Using this approach, we believe physicians will be able to quickly direct ovarian cancer patients towards appropriate lines of therapy."

Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies and the fifth most frequent cause of cancer death in women. In 2008, ovarian cancer will be diagnosed in more than 20,000 women in the United States.(1) Approximately 15,000 women will die from the disease. In the U.S., we spend an estimated $2.2 billion per year to treat ovarian cancer.

The Companies plan to work collaboratively with the goal of improving patient outcomes through personalized medicine. Transgenomics' highly sensitive technologies for DNA mutation detection and analysis are expected to complement and enhance COXEN, which combines genomic and pharmacological response data on a set of widely used cancer cell lines to generate molecular signatures of patient response to specific anti-cancer agents.(2) This innovative test is intended to provide the optimal therapy recommendation according to the molecular characteristics of each patient's tumor.

Tim Gallagher, Key Genomics CEO, said, "An algorithm that could quickly sort molecular information about a patient's particular tumor, and then match this information with the right drug treatment would be a valuable medical breakthrough. COXEN has the potential to bring significant healthcare and economic value by personalizing cancer therapy by using such a method, an algorithm based on in vitro response to anti-cancer drugs."

References

1. National Cancer Institute web site: http://www.cancer.gov/cancertopics/types/ovarian/

2. Lee JK et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91. Epub 2007 Jul 31.

About Transgenomic

Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, Cytogenetics automated systems, and Transgenomic Pharmacogenomics and Reference Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: http://www.transgenomic.com.

About Key Genomics

Key Genomics works with pharmaceutical and molecular diagnostics companies to improve patient outcomes through new solutions for personalized medicine, drug discovery, and clinical trials by accurately predicting patient response based on cellular assays and patient genomic data. Learn more at http://www.keygenomics.com.

Transgenomic Cautionary Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.


'/>"/>
SOURCE Transgenomic
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic Reports Second Quarter 2008 Results
2. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
3. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
4. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
5. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
6. Transgenomic Opens Pharmacogenomics Laboratory in China
7. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
8. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
9. Transgenomic Appoints David Pauluzzi to Board of Directors
10. Transgenomic, Inc. Forms Scientific Advisory Board
11. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
Breaking Biology Technology:
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
Breaking Biology News(10 mins):